Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.

Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

It was the first in a series of drugs that are, for the first time, effective against obesity and can help lessen the moral ...

Novo Nordisk itself, meanwhile, recently started a phase 2 study of CagriSema – its combination of semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – that will ...

Already developing a trio of incretin drugs for obesity, Eli Lilly has its sights set on a candidate with a different mechanism of ... in phase 3 known as CagriSema, which is based on semaglutide ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Last December, Novo Nordisk revealed phase 3 results for cagrisema, a combination of semaglutide and an amylin analog called cagrilintide. Sadly, it doesn't look like cagrisema works any better ...

Enzyme mechanisms are the chemical transformations, and the steps within them, generated by enzymatic action on substrates. The mechanism of enzyme catalysis is similar in principle to other types ...

December 20, 2024 Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the ...